Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vyxeos + gemtuzumab ozogamicin
- Development stage
- Unknown
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Vyxeos + gemtuzumab ozogamicin is an investigational combination therapy being evaluated for the treatment of relapsed or refractory pediatric acute myeloid leukemia (AML). The regimen combines Vyxeos (CPX-351), a liposomal formulation of cytarabine and daunorubicin in a fixed 5:1 molar ratio, with gemtuzumab ozogamicin (Mylotarg), a CD33-directed antibody-drug conjugate (ADC). Vyxeos is designed to deliver synergistic ratios of chemotherapy directly to the bone marrow, where cytarabine inhibits DNA synthesis and daunorubicin inhibits topoisomerase II. Gemtuzumab ozogamicin targets CD33-positive myeloid blasts, delivering the potent cytotoxic payload calicheamicin to induce DNA double-strand breaks. This combination approach, spearheaded in clinical trials by the M.D. Anderson Cancer Center, aims to improve outcomes in difficult-to-treat pediatric AML populations by combining targeted immunotherapy with optimized liposomal chemotherapy.
- Brand names
- VyxeosMylotarg
- Other names
- Liposomal cytarabine and daunorubicin + gemtuzumab ozogamicinCPX-351 + gemtuzumab ozogamicin
02
Targets
DNADNA polymerase familyCD33 (Myeloid cell surface antigen CD33)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on Vyxeos + gemtuzumab ozogamicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vyxeos + gemtuzumab ozogamicin.